-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The @US_FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in R/R AML or high-risk myelodysplastic syndromes. #mdsm https://t.co/I4JbfQp26h
-
-
Mashup Score: 4
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/6ihsniExw5
-
-
Mashup Score: 2
The FDA has granted permission for enrollment to resume in the monotherapy phase 1a portion of the phase 1/2 TakeAim Leukemia trial evaluating emavusertib in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA Allows Trial Enrollment to Resume for Single-Agent Emavusertib in AML/MDS #leusm #mdsm #oncology https://t.co/sJ3mQqRFdH
-
-
Mashup Score: 0
Rami Komrokji, MD, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes, and highlights other key updates in chronic lymphocytic leukemia, mantle cell lymphoma, diffuse large B-cell lymphoma, and myelofibrosis.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Novel Combinations Could Spark Shift in Treatment Paradigm for Higher-Risk MDS @MoffittNews #mdsm #oncology https://t.co/g9Ohpg3eVw
-
-
Mashup Score: 0
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Magrolimab represents a potential step forward in the treatment of patients with high-risk MDS, where the current standard of care of azacitidine or decitabine fails to generate significant responses. @DanPollyea @CUMedicalSchool #mdsm https://t.co/21UZCAjFX2 https://t.co/NR9OfZ3I5P
-
-
Mashup Score: 0
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.@DanPollyea @CUMedicalSchool #mdsm https://t.co/x6y0eY5bZk
-
-
Mashup Score: 0
Dan Pollyea, MD, MS, discussed the difficulties in developing new agents for the treatment of high-risk MDS, the objective of the ENHANCE trial, and the potential for other therapies to emerge in the treatment paradigm.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Novel Agents Needed to Expand Treatment Options for Patients With High-Risk MDS @DanPollyea @CUMedicalSchool #mdsm #Oncology https://t.co/uRpM1OG7tu
-
Rami Komrokji, MD, of @MoffittNews, expands on the disease factors and treatment options for lower-risk and higher-risk myelodysplastic syndromes #mdsm https://t.co/jXMdLskiPJ https://t.co/JSRWI2aABt